JP2005502585A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005502585A5 JP2005502585A5 JP2002557425A JP2002557425A JP2005502585A5 JP 2005502585 A5 JP2005502585 A5 JP 2005502585A5 JP 2002557425 A JP2002557425 A JP 2002557425A JP 2002557425 A JP2002557425 A JP 2002557425A JP 2005502585 A5 JP2005502585 A5 JP 2005502585A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- subject
- kit
- viral vector
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001225 therapeutic effect Effects 0.000 claims 39
- 239000013603 viral vector Substances 0.000 claims 34
- 108700019146 Transgenes Proteins 0.000 claims 25
- 239000003795 chemical substances by application Substances 0.000 claims 25
- 108090000623 proteins and genes Proteins 0.000 claims 24
- 241000700605 Viruses Species 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 19
- 108020004707 nucleic acids Proteins 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 19
- 102000039446 nucleic acids Human genes 0.000 claims 19
- 210000001865 kupffer cell Anatomy 0.000 claims 16
- 230000003612 virological effect Effects 0.000 claims 16
- 230000006870 function Effects 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000013598 vector Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 241000288906 Primates Species 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 238000002347 injection Methods 0.000 claims 6
- 239000007924 injection Substances 0.000 claims 6
- 238000007918 intramuscular administration Methods 0.000 claims 6
- 238000001990 intravenous administration Methods 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 210000000056 organ Anatomy 0.000 claims 6
- 238000007911 parenteral administration Methods 0.000 claims 6
- 238000007920 subcutaneous administration Methods 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 6
- 238000011200 topical administration Methods 0.000 claims 6
- 238000007912 intraperitoneal administration Methods 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 5
- 230000001988 toxicity Effects 0.000 claims 4
- 231100000419 toxicity Toxicity 0.000 claims 4
- 241000283984 Rodentia Species 0.000 claims 3
- 230000003915 cell function Effects 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- 206010019851 Hepatotoxicity Diseases 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000007686 hepatotoxicity Effects 0.000 claims 2
- 231100000304 hepatotoxicity Toxicity 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 238000009738 saturating Methods 0.000 claims 2
- 210000004303 peritoneum Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26341601P | 2001-01-22 | 2001-01-22 | |
| PCT/US2002/001797 WO2002056918A2 (en) | 2001-01-22 | 2002-01-22 | Method of enhancing delivery of a therapeutic nucleic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005502585A JP2005502585A (ja) | 2005-01-27 |
| JP2005502585A5 true JP2005502585A5 (enExample) | 2005-12-22 |
Family
ID=23001688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002557425A Pending JP2005502585A (ja) | 2001-01-22 | 2002-01-22 | 治療的核酸の送達を増強するための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7534424B2 (enExample) |
| EP (1) | EP1363676B1 (enExample) |
| JP (1) | JP2005502585A (enExample) |
| AT (1) | ATE357935T1 (enExample) |
| AU (1) | AU2002237910B2 (enExample) |
| CA (1) | CA2435443A1 (enExample) |
| CY (1) | CY1106676T1 (enExample) |
| DE (1) | DE60219142T2 (enExample) |
| DK (1) | DK1363676T3 (enExample) |
| ES (1) | ES2283524T3 (enExample) |
| NZ (1) | NZ527645A (enExample) |
| PT (1) | PT1363676E (enExample) |
| WO (1) | WO2002056918A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696423B1 (en) * | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
| JP4736413B2 (ja) * | 2004-12-14 | 2011-07-27 | 富士ゼロックス株式会社 | 生体分子保持物及び生体分子の保存方法 |
| JPWO2011074564A1 (ja) * | 2009-12-15 | 2013-04-25 | タカラバイオ株式会社 | アデノウイルスベクターの製造方法 |
| US20140141065A1 (en) * | 2012-11-19 | 2014-05-22 | Discovery Genomics, Inc. | Method to achieve extended expression of dna infused into liver |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) * | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4797368A (en) * | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5262564A (en) * | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| DE19525900C1 (de) * | 1995-07-15 | 1996-12-12 | Max Planck Gesellschaft | Leberspezifischer Adenovirus-Expressionsvektor |
| NZ503401A (en) * | 1997-08-29 | 2003-01-31 | Biogen Inc | Use of interferon-beta (IFN-B) genes for the treatment of cancer |
| US6696423B1 (en) * | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
| WO2001060377A2 (en) * | 2000-02-17 | 2001-08-23 | Genzyme Corporation | Methods for treatment of lysosomal storage diseases using biphosphonates |
-
2002
- 2002-01-22 CA CA002435443A patent/CA2435443A1/en not_active Abandoned
- 2002-01-22 AT AT02704215T patent/ATE357935T1/de not_active IP Right Cessation
- 2002-01-22 JP JP2002557425A patent/JP2005502585A/ja active Pending
- 2002-01-22 DE DE60219142T patent/DE60219142T2/de not_active Expired - Fee Related
- 2002-01-22 AU AU2002237910A patent/AU2002237910B2/en not_active Ceased
- 2002-01-22 NZ NZ527645A patent/NZ527645A/en unknown
- 2002-01-22 EP EP02704215A patent/EP1363676B1/en not_active Expired - Lifetime
- 2002-01-22 DK DK02704215T patent/DK1363676T3/da active
- 2002-01-22 WO PCT/US2002/001797 patent/WO2002056918A2/en not_active Ceased
- 2002-01-22 PT PT02704215T patent/PT1363676E/pt unknown
- 2002-01-22 ES ES02704215T patent/ES2283524T3/es not_active Expired - Lifetime
-
2003
- 2003-07-11 US US10/618,299 patent/US7534424B2/en not_active Expired - Lifetime
-
2007
- 2007-06-25 CY CY20071100841T patent/CY1106676T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU7440600A (en) | Pulmonary delivery for bioconjugation | |
| KR20120047891A (ko) | Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복 | |
| JP2005533021A5 (enExample) | ||
| JPH10506640A (ja) | Ｃ型肝炎の処置のためのリバビリンおよびインターフェロンαの使用 | |
| JP2001521502A (ja) | Ｃ型肝炎の治療へのアマンタジンの使用 | |
| WO2004108088A3 (en) | Methods and compositions for interferon therapy | |
| US8324151B2 (en) | Treatment of sepsis and septic shock using ghrelin and growth hormone | |
| Zhang et al. | Prevent and Reverse Metabolic Dysfunction-Associated Steatohepatitis and Hepatic Fibrosis via mRNA-Mediated Liver-Specific Antibody Therapy | |
| JP2005502585A5 (enExample) | ||
| Zein | Interferons in the management of viral hepatitis | |
| JP2008266179A (ja) | 経肺用組成物 | |
| JP2004529158A5 (enExample) | ||
| WO2002056918B1 (en) | Method of enhancing delivery of a therapeutic nucleic acid | |
| WO2020061685A1 (en) | Methods for selective kinase inhibition by endogenously produced antagonists of one or more kinases | |
| CN114177272B (zh) | Mm07在制备治疗矽肺的药物中的应用 | |
| Wildhirt | Experience in Germany with glycyrrhizinic acid for the treatment of chronic viral hepatitis | |
| Potter et al. | Ocular and cardiac β-antagonism by timolol prodrugs, timolol and levobunolol | |
| WO2025247037A1 (zh) | Yap通路激活剂在制备抗嗜肝病毒药物中的应用 | |
| Freiman et al. | Postexposure treatment of experimental DHBV infection: a new therapeutic strategy | |
| CN111450232B (zh) | 一种融合蛋白在制备治疗丙型肝炎药物中的应用 | |
| JPH10503475A (ja) | 血液眼関門透過性強化用パーミアビライザーペプチド | |
| CN118416255A (zh) | 含Cas9/sgGDF15复合物的靶向肝癌的纳米胶囊及其制备方法和应用 | |
| US7838494B2 (en) | Differentiation- or regeneration-inducing agent for alveoli | |
| CN107661324A (zh) | 普罗帕酮在制备治疗食管癌药物中的应用 | |
| CN118059235A (zh) | 一种用于减轻骨关节炎的双功能磁热纳米开关的制备方法及应用 |